Search

Your search keyword '"Rangaswami, Janani"' showing total 738 results
Start Over Author "Rangaswami, Janani"
738 results on '"Rangaswami, Janani"'

1. Metabolic syndrome

Author

Neeland, Ian J., Lim, Soo, Tchernof, André, Gastaldelli, Amalia, Rangaswami, Janani, Ndumele, Chiadi E., Powell-Wiley, Tiffany M., and Després, Jean-Pierre

Published
2024
Full Text
View/download PDF

14. Development and Validation of the American Heart Association’s PREVENT Equations

Author

Khan, Sadiya S., Matsushita, Kunihiro, Sang, Yingying, Ballew, Shoshana H., Grams, Morgan E., Surapaneni, Aditya, Blaha, Michael J., Carson, April P., Chang, Alexander R., Ciemins, Elizabeth, Go, Alan S., Gutierrez, Orlando M., Hwang, Shih-Jen, Jassal, Simerjot K., Kovesdy, Csaba P., Lloyd-Jones, Donald M., Shlipak, Michael G., Palaniappan, Latha P., Sperling, Laurence, Virani, Salim S., Tuttle, Katherine, Neeland, Ian J., Chow, Sheryl L., Rangaswami, Janani, Pencina, Michael J., Ndumele, Chiadi E., and Coresh, Josef

Published
2024
Full Text
View/download PDF

16. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association

Author

Khan, Sadiya S., Coresh, Josef, Pencina, Michael J., Ndumele, Chiadi E., Rangaswami, Janani, Chow, Sheryl L., Palaniappan, Latha P., Sperling, Laurence S., Virani, Salim S., Ho, Jennifer E., Neeland, Ian J., Tuttle, Katherine R., Rajgopal Singh, Radhika, Elkind, Mitchell S.V., and Lloyd-Jones, Donald M.

Published
2023
Full Text
View/download PDF

17. Home dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Abrahams, Alferso C., Anumudu, Samaya J., Bargman, Joanne M., Moore, Geraldine Biddle, Blake, Peter G., Borman, Natalie, Bowes, Elaine, Burton, James O., Caillette-Beaudoin, Agnes, Cho, Yeoungjee, Cullis, Brett, Einbinder, Yael, el Shamy, Osama, Erickson, Kevin F., Figueiredo, Ana E., Finkelstein, Fred, Fluck, Richard, Flythe, Jennifer E., Fotheringham, James, Fukagawa, Masafumi, Goffin, Eric, Golper, Thomas A., Gómez, Rafael, Jha, Vivekanand, Johnson, David W., Kanjanabuch, Talerngsak, Kim, Yong-Lim, Lambie, Mark, Lerma, Edgar V., Lockridge, Robert S., Loud, Fiona, Masakane, Ikuto, Matthews, Nicola, McKane, Will, Mendelssohn, David C., Mettang, Thomas, Mitra, Sandip, Moraes, Thyago Proença de, Morton, Rachael, Mushahar, Lily, Nadeau-Fredette, Annie-Claire, Nayak, K.S., Neumann, Joanna L., Ngaruiya, Grace, Okpechi, Ikechi, Quinn, Robert R., Rangaswami, Janani, Reddy, Yuvaram N.V., Schiller, Brigitte, Shen, Jenny I., Shroff, Rukshana, Slon Roblero, Maria Fernanda, Solá, Laura, Søndergaard, Henning, Teitelbaum, Isaac, Tennankore, Karthik, Van Ommeslaeghe, Floris, Walker, Rachael C., Walker, Robert J., Wang, Angela Yee-Moon, Warady, Bradley A., Watnick, Suzanne, Weinhandl, Eric D., Wilkie, Caroline M., Williams, Jennifer, Perl, Jeffrey, Brown, Edwina A., Chan, Christopher T., Couchoud, Cécile, Davies, Simon J., Kazancioğlu, Rümeyza, Klarenbach, Scott, Liew, Adrian, Weiner, Daniel E., Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Wilkie, Martin E.

Published
2023
Full Text
View/download PDF

21. Class effects of SGLT2 inhibitors on cardiorenal outcomes

Author

Kluger, Aaron Y, Tecson, Kristen M, Lee, Andy Y, Lerma, Edgar V, Rangaswami, Janani, Lepor, Norman E, Cobble, Michael E, and McCullough, Peter A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cardiovascular, Clinical Research, Kidney Disease, Clinical Trials and Supportive Activities, Diabetes, Heart Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Benzhydryl Compounds, Canagliflozin, Cardiovascular Diseases, Cardiovascular System, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Disease Progression, Glucosides, Humans, Kidney, Protective Factors, Randomized Controlled Trials as Topic, Renal Insufficiency, Chronic, Risk Assessment, Risk Factors, Sodium-Glucose Transporter 2 Inhibitors, Time Factors, Treatment Outcome, SGLT2 inhibitor, Empagliflozin, Dapagliflozin, CANVAS, EMPA-REG OUTCOME, DECLARE-TIMI 58, CREDENCE, Cardiovascular outcome trials, Heart failure hospitalization, Cardiovascular death, Albuminuria, Estimated glomerular filtration function, Chronic kidney disease, End-stage renal disease, Mortality, EMPA–REG OUTCOME, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

BackgroundTo summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), and explore the potential determinants for their cardiovascular, renal, and safety outcomes.ResultsThe composite renal outcome event rates per 1000 patient-years for drug and placebo, as well as the corresponding relative risk reductions, were 3.7, 7.0, 47%; 5.5, 9.0, 40%; 6.3, 11.5, 46%; 43.2, 61.2, 30% for DECLARE-TIMI 58, CANVAS, EMPA-REG OUTCOME, and CREDENCE, respectively (event definitions varied across trials). The major adverse cardiovascular (CV) event rates per 1000 patient-years for drug and placebo, as well as the corresponding relative risk reductions, were 22.6, 24.2, 7%; 26.9, 31.5, 14%; 37.4, 43.9, 14%; 38.7, 48.7, 20% for DECLARE-TIMI 58, CANVAS, EMPA-REG OUTCOME, and CREDENCE, respectively. DECLARE-TIMI 58 had the fewest cardiorenal events and CREDENCE the most. These differences were presumably due to varying inclusion criteria resulting in DECLARE-TIMI 58 having the best baseline renal filtration function and CREDENCE the worst (mean estimated glomerular filtration rate 85.2, 76.5, 74, 56.2 mL/min/1.73 m2 for DECLARE-TIMI 58, CANVAS, EMPA-REG OUTCOME, and CREDENCE, respectively). Additionally, CREDENCE had considerably higher rates of albuminuria (median urinary albumin-creatinine ratios (UACR) were 927, 12.3, and 13.1 mg/g for CREDENCE, CANVAS, and DECLARE-TIMI 58, respectively; EMPA-REG OUTCOME had 59.4% UACR  30-300, 11.0% UACR > 300 mg/g).ConclusionsDapagliflozin, empagliflozin, and canagliflozin have internally and externally consistent and biologically plausible class effects on cardiorenal outcomes. Baseline renal filtration function and degree of albuminuria are the most significant indicators of risk for both CV and renal events. Thus, these two factors also anticipate the greatest clinical benefit for SGLT2i.

Published
2019

22. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association

Author

Ndumele, Chiadi E., Neeland, Ian J., Tuttle, Katherine R., Chow, Sheryl L., Mathew, Roy O., Khan, Sadiya S., Coresh, Josef, Baker-Smith, Carissa M., Carnethon, Mercedes R., Després, Jean-Pierre, Ho, Jennifer E., Joseph, Joshua J., Kernan, Walter N., Khera, Amit, Kosiborod, Mikhail N., Lekavich, Carolyn L., Lewis, Eldrin F., Lo, Kevin B., Ozkan, Bige, Palaniappan, Latha P., Patel, Sonali S., Pencina, Michael J., Powell-Wiley, Tiffany M., Sperling, Laurence S., Virani, Salim S., Wright, Jackson T., Rajgopal Singh, Radhika, Elkind, Mitchell S.V., and Rangaswami, Janani

Published
2023
Full Text
View/download PDF

23. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association

Author

Ndumele, Chiadi E., Rangaswami, Janani, Chow, Sheryl L., Neeland, Ian J., Tuttle, Katherine R., Khan, Sadiya S., Coresh, Josef, Mathew, Roy O., Baker-Smith, Carissa M., Carnethon, Mercedes R., Despres, Jean-Pierre, Ho, Jennifer E., Joseph, Joshua J., Kernan, Walter N., Khera, Amit, Kosiborod, Mikhail N., Lekavich, Carolyn L., Lewis, Eldrin F., Lo, Kevin B., Ozkan, Bige, Palaniappan, Latha P., Patel, Sonali S., Pencina, Michael J., Powell-Wiley, Tiffany M., Sperling, Laurence S., Virani, Salim S., Wright, Jackson T., Rajgopal Singh, Radhika, and Elkind, Mitchell S.V.

Published
2023
Full Text
View/download PDF

41. #255 PaCE CKD: the impact of caregiving on health states and work productivity in chronic kidney disease: results from an international survey

Author

Sanchez, Juan Jose Garcia, primary, Wu, Mai-Szu, additional, Chadban, Steven, additional, Correa-Rotter, Ricardo, additional, Reichel, Helmut, additional, Elsayed, Hesham, additional, Rangaswami, Janani, additional, Esposito, Ciro, additional, Hull, Richard, additional, Pentakota, Surendra, additional, West, Bronwyn, additional, Kularatne, Thames, additional, and Fifer, Simon, additional

Published
2024
Full Text
View/download PDF

42. #254 PaCE CKD: examining health status and financial burden in patients with chronic kidney disease: assessing the non-clinical burden of disease

Author

Sanchez, Juan Jose Garcia, primary, Reichel, Helmut, additional, Rangaswami, Janani, additional, Esposito, Ciro, additional, Elsayed, Hesham, additional, Wu, Mai-Szu, additional, Hull, Richard, additional, Chadban, Steven, additional, Correa-Rotter, Ricardo, additional, Pentakota, Surendra, additional, West, Bronwyn, additional, Kularatne, Thames, additional, and Fifer, Simon, additional

Published
2024
Full Text
View/download PDF

49. Barriers to utilization of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction in the outpatient setting: A single center analysis.

Author

Lima Falcao Angelim, Sarah Correia, Tito, Sahana, Canonigo Casipit, Bruce Adrian, Cantu Martinez, Omar, Ogunmola, Isaac Omolade, Barreira Angelim, Lucas, Shah, Samir, Lo, Kevin Bryan, and Rangaswami, Janani

Subjects
TYPE 2 diabetes, HEART failure patients, SODIUM-glucose cotransporter 2 inhibitors, CHRONIC kidney failure, VENTRICULAR ejection fraction
Abstract

Background In patients with heart failure with reduced ejection fraction (HFrEF), SGLT2 inhibitors have consistently demonstrated improved cardiovascular and renal outcomes regardless of diabetes status. However, SGLT2i remain significantly under-utilized in this patient population. We seek to study the current state of SGLT2i use and barriers to utilization using real- world data in an inner -city community hospital setting. Methods This is a single center retrospective analysis of patients diagnosed with HFrEF, defined as ejection fraction ≤ 40%, seen from December 2019 to December 2021, in the outpatient setting. Results A total of 464 patients were included in this analysis, where SGLT2 inhibitors were indicated for type 2 diabetes mellitus, chronic kidney disease (CKD), and/or heart failure. Twenty five percent of patients were on SGLT2 inhibitors, despite low frequency of absolute or relative contraindications (5%) and 14% of patients had ≥CKD4with eGFR<30ml/min/1.73m². History of CAD [OR 0.30; 95% CI 0.18-0.50; p<0.001], ≥CKD4 [OR 0.35; 95% CI 0.16-0.73; p=0.005] and higher ejection fraction on the spectrum of HFrEF [OR 0.95; 95% CI 0.92-0.97; p<0.001] were significantly inversely associated with SGLT2i use. Conclusions There was significant under-utilization of SGLT2i in this single center analysis, despite lack of absolute and relative contraindications in the majority of our study population and the presence of multiple possible indications including concomitant type 2 diabetes and CKD. More pragmatic studies are needed emphasizing practical implementation of medical management for high-risk patient populations. [ABSTRACT FROM AUTHOR]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results